Alto Neuroscience ANRO EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Alto Neuroscience’s reported figures.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's EBITDA?
- Alto Neuroscience (ANRO) reported EBITDA of -$26.95M in Q1 2026.
- How has Alto Neuroscience's EBITDA changed year-over-year?
- Alto Neuroscience's EBITDA decreased by 73.8% year-over-year, from -$15.51M to -$26.95M.
- What is the long-term trend for Alto Neuroscience's EBITDA?
- Over 2 years (2023 to 2025), Alto Neuroscience's EBITDA has grown at a 32.6% compound annual growth rate (CAGR), from -$37.41M to -$65.74M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.